Research programme: anticancer protein therapeutics - CuraGen
Alternative Names: Anticancer protein therapeutics research programme - CuraGen; CG 51896; CG 53449; CG 55069; CG 55069-11; CG 57067Latest Information Update: 27 Aug 2009
Price :
$50 *
At a glance
- Originator CuraGen Corporation
- Class Proteins
- Mechanism of Action Angiogenesis inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 06 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section ,
- 20 Aug 2003 This programme is still in active development
- 17 Apr 2002 Preclinical trials in Solid tumours in USA (unspecified route)